1 / 48

The International Pharmacopoeia Quality standards for TB medicines

The International Pharmacopoeia Quality standards for TB medicines. Caroline Mendy - Technical Officer - Quality Assurance and Safety: Medicines. Tutorial workshop, Beijing, March 2010. Quality standards for TB medicines – an issue?.

solana
Download Presentation

The International Pharmacopoeia Quality standards for TB medicines

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The International Pharmacopoeia Quality standards for TB medicines Caroline Mendy - Technical Officer - Quality Assurance and Safety: Medicines Tutorial workshop, Beijing, March 2010

  2. QualitystandardsforTBmedicines – an issue? • "[…] reliable quality of medicines is absolutely essential for effective TB programmes" TB Alliance • "[…] low quality drugs damage patient recovery and increase the likelihood of drug-resistant strains of TB Stop-TB partnership Several WHO studies carried out or on-going to monitor the quality of marketed TB medicines

  3. QualitystandardsforTBmedicines • Monographs available in Ph.Int. • Monographs, requirements and identity tests • Assay and related substances • method development • Dissolution / disintegration specifications • Isoniazid and Ethambutol hydrochloride tablets Focus: TB FDC tablets

  4. Ph.Int. TB monographs Priorities for inclusion of new specifications for TB medicines: • WHO Essential medicines lists • WHO specific disease programmes (e.g. Stop-TB, Prequalification) Specifications for first-line and second-line TB drugs available (APIs and FPP)

  5. Ph.Int. TB monographs Amikacin (revision) - Oct 2009 Amikacin sulfate (revision) - Oct 2009 Amikacin injection - Oct 2009 kanamycin monosulfate - Oct 2009 kanamycin acid sulfate - Oct 2009 Kanamycin injection - Oct 2009 • Isoniazid • Isoniazid tablets • Pyrazinamide • Pyrazinamide tablets • Rifampicin • Streptomycin sulfate • Streptomycin sulfate powder for injection • Thioacetazone • Cycloserine • Cycloserine capsules • Ethambutol HCl (revision)

  6. Ph.Int. TB monographs – to come… Capreomycin - draft in progress Capreomycin injection - draft in progress Ethionamide tablets* Protionamide tablets* Terizidone* Ofloxacin tablets* Levofloxacin tablets* p-aminosalicylic acid granules/tablets* *on 2010 work programme

  7. Ph.Int. monographs: TB FDC dosage forms 4FDC: Rifampicin / Isoniazid / Pyrazinamide / Ethambutol HCl tablets 3FDC: Rifampicin / Isoniazid / Pyrazinamide tablets Rifampicin / Isoniazid / Pyrazinamide dispersible tablets (new) Rifampicin / Isoniazid / Ethambutol HCl tablets (new) 2FDC: Rifampicin / Isoniazid tablets Rifampicin / Isoniazid dispersible tablets (new) Isoniazid / Ethambutol HCl tablets Rifampicin tablets Rifampicin capsules Basic approach for monograph development: top down 9 monographs !

  8. Ph.Int. monographs: TB FDC dosage forms Strategy • Start with the most complex combination (4FDC tablets) • Work down to most simple situation using same procedures 4FDC Isoniazid 3FDC Rifampicin 2FDC Ethambutol Pyrazinamide

  9. TB 4FDC tabletsPh.Int. monograph: Information section √ ? √

  10. TB 4FDC tabletsMonograph: Requirements read General monographfor Tablets √ √ ?

  11. TB 4FDC tabletsMonograph: Identity tests Requirement: • Specific for each API in the 4FDC tablet • identification should be conclusive on presence / absence of the APIs • More than one test may apply for conclusive identification • tests X and Y • There may be a choice between tests • either test X or test Y may be applied read instruction in monograph carefully

  12. TB 4FDC tabletsMonograph: Identity tests The TB 4FDC monograph states the following: • Either tests A and B or test C may be applied Tests A and B are the 2 HPLC assay tests • retention time compared to ICRS (reference substance) Test C is a TLC test • position (Rf), appearance & intensity of spot compared to ICRS • note 3 parameters in one test • Choice with respect to visualisation of spots • UV or visible (after exposure to iodine vapour) Test C first

  13. TB 4FDC tabletsMonograph: Identity test (copy from monograph) HF254

  14. TB 4FDC tabletsMonograph: Identity test (results) Method C.2 In daylight,after exposure to I2 Method C.1 In UV (254 nm),after exposure to I2 Eth INH PY Rif Tab In UV (254 nm),before exposure to I2

  15. Structures of the APIs in TB 4FDC tablet Isoniazid Yes Yes Rifampicin UV absorbing groups? Yes No Pyrazinamide Ethambutol

  16. TB 4FDC tabletsMonograph: Related substances General recommendation for FDCs • Related substances (degradation products) should be tested in the FDC products for • APIs which are unstable • Very stable APIs may not be required • What is the situation in the case of the TB 4FDC tablets? • Consult literature for stability • Do stress testing under various conditions (part of validation) • Temperature, pH, oxidation, light, … • API-API interactions

  17. Information from literature & structure Rifampicin hydrolysis (to 25-desacetyl) light sensitive oxidation (to N-oxide) quinone hydrolysis(to 3-formyl rifamycin) oxidation (to quinone)

  18. Information from literature & structure 3-Formyl rifamycin + H2N ― R o R Isoniazid

  19. Information from literature & structure “isonicotinoyl hydrazone” N ― R o R Isoniazid

  20. Information from literature & structure Rifampicin - summary Rifampicin known degradation products • Oxidation • Rifampicin quinone • Rifampicin N-Oxide • Hydrolysis • 3-Formyl rifamycin • 25-desacetyl rifampicin • Reaction with Isoniazid • isonicotinoyl hydrazone • 3-(isonicotinoylhydrazinomethyl)rifamycin light sensitive

  21. Information from literature & structureRifampicin Special storage conditions for the API? International Pharmacopoeia: • Rifampicin should be kept in • a tightly closed container • (exclude exposure to air - moisture and oxygen) • (container of low permeability) • protected from light and • stored at a temperature not exceeding 15°C, or • in an atmosphere of nitrogen at a temperature not exceeding 30°C • (absence of air oxygen)

  22. Rifampicin impurities (TLC) • Reference: Int.Ph. related substances test for rifampicin • Silica gel R1 • CHCl3/methanol : 85/15 • Daylight detection a Rifampicin test substance: 20 mg/ml b Quinone: 0.8 mg/ml (4.0%) c N-oxide: 0.3 mg/ml (1.5%) d 3-Formyl rifamycin: 0.1 mg/ml (0.5%) e Rifampicin: 0.2 mg/ml (1.0%) a b c d e

  23. Information from literatureIsoniazid Small molecule • Quite stable • Can hydrolyze under stress conditions to inter alia isonicotinic acid & hydrazine • Primary amine - react with aldehydes, for example • reducing sugars / lactose • 3-Formyl rifamycin(rifampicin degradation product)

  24. Information from literaturePyrazinamide Small molecule • Quite stable • Amide group can hydrolyse under strong conditions to pyrazinoic acid & ammonia • Test D in Ph.Int. monograph for Pyrazinamide API: • Boil 20 mg with 5 ml of sodium hydroxide (~200 g/l) TS; ammonia, perceptible by its odour, is evolved.

  25. Information from literatureEthambutol hydrochloride Small molecule • Quite stable • (2-aminobutanol – synthesis impurity) • Hygroscopic (solubility in water: 50% m/m) • In FDC tablets ethambutol can absorb water • absorbed water helps degradation of rifampicin • Forms metal complexes • Very useful in FDC assay test S,S-isomer pharmaceutical :N—C │ :N—C Cu++

  26. Information from literatureWhat is important for monograph development? • Rifampicin related substances to be tested for • Rifampicin quinone • Rifampicin N-Oxide • 3-Formyl rifamycin • isonicotinoyl hydrazone = product with isoniazid • 25-desacetyl rifampicin • Protect from light (mainly due to rifampicin) • Product (packaging) and sample / test solutions • Protect from moisture • “Manufacture”► protective packaging + set moisture limit • QC testing► protect tablet powder from moisture uptake

  27. TB 4FDC tabletsExamples of water uptake ProductsB A FPPs (packed products) Unpacked tablets (control) After 5 days at 40°C/75% RH After 5 days at 40°C/75% RH + Light S. Singh, Int. J. Tuberc. Lung. Dis., 7, 298 (2003) Quality of the products not known “bleeding”

  28. TB 4FDC tabletsExample of poor FPP Have you seen a TB 4FDC tablet like this when opening the primary packaging? Hopefully not • Example: TB 4-FDC tablets • one year from expiry Photo from: S. Singh & B. Mohan, Int. J. Tuberc. Lung. Dis., 7, 298 (2003)

  29. TB 4FDC tabletsMonograph: Requirements read General monographfor Tablets √ √ ? √

  30. TB 4FDC tabletsAssay and related substances The objectives • To develop assay methods for • all four APIs in the TB 4FDC tablet • HPLC as only option • To develop methods for determination of degradationproducts (related substances) • Only for rifampicin • HPLC as only option

  31. Assay TB 4FDC tabletsAssay and related substances The approach to HPLC methods • Minimise the number of HPLC methods • Not 4 HPLC methods for assay of the 4 APIs • The column(s) should be easily obtainable • The use of an isocratic profile instead of a gradient profile • the test can be carried out by any laboratory • The assay method(s) should be stability-indicating • It would be advantageous if the related substances could be determined with the method(s) used for assay

  32. Assay TB 4FDC tabletsAssay and related substances Strategy followed • Screening of existing methods • Literature • Manufacturers • Selecting promising candidates • Desk and experimental evaluation • Optimisation of selected method(s) • Validation

  33. Assay TB 4FDC tabletsAssay and related substances The outcome • Two HPLC methods have been developed • One method for simultaneous assay of one or more of • Isoniazid • Pyrazinamide • Ethambutol hydrochloride • Another method for rifampicin • Assay • Related substances (degradation products)

  34. Assay TB 4FDC tabletsIsoniazid/Pyrazinamide/Ethambutol HPLC Ethambutol properties were key to assay method • Problem • Ethambutol lacks useful absorption in UV/visible region • USP method - detection at 200 nm • Answer • Ethambutol compexes with Cu2+ • Maximum absorption at 270-280 nm • Method principle • Copper(II) acetate in mobile phase

  35. Assay TB 4FDC tabletsIsoniazid/Pyrazinamide/Ethambutol HPLC buffer pH 5.0 Cu2+ in mobile phase Pyrazinamid Detection at 270 nm resolution ≥ 2 Ethambutol Isoniazid 10 min

  36. Assay TB 4FDC tabletsIsoniazid/Pyrazinamide/Ethambutol HPLC Validation • All parameters were validated • ICH Q2(R1) • Specificity of particular interest • No “innovator” product • Placebo constructed from all known excipients in 4FDC tablets • information from package inserts • Stress testing • water, alkali, acid, hydrogen peroxide at 40°C on one product • DAD (Diode Array Detection) for peak purity

  37. Assay / related substances TB 4FDC tabletsRifampicin HPLC Rifampicin related substances to be tested for • Rifampicin quinone • Rifampicin N-Oxide • 3-Formyl rifamycin • 3-(isonicotinoylhydrazinomethyl)rifamycin • "hydrazone“ obtained from 3-formylrifamycin & isoniazid reaction • Sample donated by Dr S. Singh, NIPER, India • 25-desacetyl rifampicin Also applicable to: • 3FDC, 2FDC tablets and rifampicin tablets and capsules

  38. Assay / related substances TB 4FDC tabletsRifampicin HPLC – Isonicotinoyl hydrazone In situ preparation of • 3-(isonicotinoylhydrazinomethyl)rifamycin • hydrazone formed from rifampicin and isoniazid reaction • solution (5) • For solution (5) dissolve 4 mg of rifampicin RS and 2 mg of isoniazid RS in 25.0 ml of acetic acid (~60g/l) TS and keep the solution at room temperature for 30 minutes • Rationale of in situ preparation based on molecules structures/interactions

  39. Assay TB 4FDC tabletsRifampicin HPLC Validation • All parameters were validated • ICH Q2(R1) • Specificity of particular interest • No “innovator” product • Placebo constructed from all known excipients in 4FDC tablets • information from package inserts • Known impurities& validation • Stress testing • water, alkali, acid, hydrogen peroxide at 40°C on one product • DAD (Diode Array Detection) for peak purity

  40. Dissolution / disintegration specificationsBCS • The Biopharmaceutics Classification System (BCS) of an API is based on its • aqueous solubility and • intestinal permeability • According to the BCS an API falls in one of four classes:

  41. Dissolution / disintegration specificationsBCS High solubility definition • The highest single unit dose of an API is completely soluble in 250 ml or less of aqueous medium over the pH range 1.0 - 6.8 (at 37°C) • No relevance to Ph.Int. solubility definitions, e.g. diazepam • Ph.Int. • Very slightly soluble (1 gram in 1000 to10 000 ml of water at 20°C) • BCS • High solubility (5 mg in ≤ 250 ml at 37°C)

  42. Dissolution / disintegration specificationsBCS Classification of TB APIs WHO Technical Report Series 937, Annex 8 (2006)

  43. Dissolution / disintegration specificationsIsoniazid/Ethambutol tablets Acceptance criteria Either (A) Dissolution or (B) Disintegration may be applied • DissolutionAll 6 units≥ 80% of label claim dissolved in 30 min. • If one tablet fails, average of 12 tablets ≥ 75%, none <60% • Criteria as set at EC meeting of Oct. 2007 • Comply with 5.4 Disintegration test for tablets and capsules, operating the apparatus for 10 minutes • If the tablets do not comply, carry out test A above • More stringent than dissolution test Generally applicable to Class 1 & 3 APIs

  44. Dissolution / disintegration specificationsIsoniazid/Ethambutol tablets Dissolution conditions of Ph.Int. for • Tablets/capsules containing a BCS highly soluble API • Samples analysed by HPLC method for assay A B C D

  45. Isoniazid/Ethambutol tabletsDiscussion of results • The dissolution profiles of the 2 APIs in a particular product are similar (this is true for all 4 products) • Both APIs are highly soluble (BCS definition) • The products show different dissolution rates • Dissolution rate A > B ≈ C >> D • Disintegration (min) 7 11 11 21 • Dissolution rate is related to disintegration time • Acceptance criteria: Disintegration tighter than dissolution • For BCS highly soluble APIs • The dissolution rate is controlled mainly by disintegration of the tablets/capsules

  46. Closing remarks • Approach for development of TB FDC tablet monographs • Top down (4FDC → 3FDC → 2FDC → rifampicin tabs/caps) • In this way all monographs can have same test methods • For rifampicin and rifampicin related substances • One HPLC method • Includes detection of isonicotinoyl hydrazone (API-API reaction) • For isoniazid, pyrazinamide & ethambutol hydrochloride • One method, no related substances • Dissolution/disintegration for isoniazid/ethambutol 2HCl tablets • Acceptance criteria: Disintegration tighter than dissolution • Ph.Int. takes lead with setting alternative criteria forClass 1 & 3 API tablets/capsules

  47. More information… Information extracted from The International Pharmacopoeia http://www.who.int/medicines/publications/pharmacopoeia/en/ WHO Prequalification: Training Material and workshops International Pharmacopoeia – Development of monographs for tuberculosis fixed-dose combination tablets – Professor. T. Dekker http://apps.who.int/prequal/

  48. Thank you!

More Related